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Abstract
Two cases of suspected acute and lethal intoxication caused by propofol were delivered by the
judicial authority to the Department of Sciences for Health Promotion and Mother–Child Care in
Palermo, Sicily. In the ﬁrst case a female nurse was found in a hotel room, where she lived with
her mother; four 10mg/mL vials and two 20mg/mL vials of propofol were found near the decedent
along with syringes and needles. In the second case a male nurse was found in the operating
room of a hospital, along with a used syringe. In both cases a preliminary systematic and toxico-
logical analysis indicated the presence of propofol in the blood and urine. As a result, a method
for the quantitative determination of propofol in biological ﬂuids was optimized and validated
using a liquid–liquid extraction protocol followed by GC/MS and fast GC/MS-TOF. In the ﬁrst case,
the concentration of propofol in blood was determined to be 8.1 μg/mL while the concentration of
propofol in the second case was calculated at 1.2 μg/mL. Additionally, the tissue distribution of
propofol was determined for both cases. Brain and liver concentrations of propofol were, respec-
tively, 31.1 and 52.2 μg/g in Case 1 and 4.7 and 49.1 μg/g in Case 2. Data emerging from the
autopsy ﬁndings, histopathological exams as well as the toxicological results aided in establishing
that the deaths were due to poisoning, however, the manner of death in each were different: homi-
cide in Case 1 and suicide in Case 2.
Introduction
Propofol (2,6-diisopropylphenol), a sedative-hypnotic agent used for
the induction of anesthesia and for sedating mechanically ventilated
patients in intensive care units (1, 2), is now increasingly being used
for conscious sedation during endoscopic procedures. Propofol is
an extremely rapid-acting intravenous anesthetic. Its advantages
include less residual postoperative sedation and less psychomotor
impairment compared to the barbiturates and less incidence of nau-
sea and vomiting (3). The blood concentration required for induc-
tion of anesthesia is generally 2–10 μg/L, while a concentration of
2–4 μg/L is sufﬁcient to maintain it (4, 5). Propofol produces dose-
dependent cardiovascular and respiratory depression with a proﬁle
similar to methohexital. Side effects include pain on injection, invol-
untary muscle movements, coughing and hiccoughing (6). It has
been associated with fatal heart failure both in children (7) and in
adult patients with head injuries (8). In fact, the constellation
of myocardial failure, metabolic acidosis and rhabdomyolysis in
children receiving propofol infusions for more than 48 h has been
termed the “propofol infusion syndrome” (9, 10). Propofol is
known to induce hypertriglyceridemia, severe enough to cause
pancreatitis, but only when used at a rate exceeding 100 μg kg–1min–1
for prolonged periods (11). Propofol is also associated with abuse and
dependency, especially among health care professionals (12–14),
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because of its rapid narcotic effect causing euphoria and sexual hallu-
cinations (15).
Several fatal cases of poisoning have been reported (13–20); in
these cases a high variability in the blood concentration of propofol
has been observed (from 0.08 to 8.7 μg/L) (4).
Two cases of suspected lethal intoxication caused by propofol
were delivered by the judicial authority to the Department of
Sciences for Health Promotion and Mother–Child Care in Palermo,
Sicily in 2014. A GC/MS method previously developed and valid-
ated in our laboratory (21) was applied for the determination of
volatile organic compounds (VOC) and the systematic toxicological
analysis (STA) on blood and urine collected from the two cases. In
both cases STA indicated the presence of propofol in blood and
urine. A method was therefore optimized and validated for the
quantitative determination of propofol in the biological ﬂuids using
a liquid–liquid extraction protocol followed by GC/MS and fast
GC/MS-TOF. Blood, urine, bile and tissue concentrations were
determined for both cases (22).
Case History
First case: female, nurse, 41 years old, sitting on a chair near a bed
in a hotel room. Four 10mg/mL vials and two 20mg/mL vials of
propofol were found near the decedent together with syringes and
needles. Signs of acupuncture on the left elbow, forearm, hand and
foot were noted. Blood, urine, bile, brain and liver were obtained at
the autopsy.
Second case: male, nurse, 55 years old, found lying in an operat-
ing room with a syringe nearby. Sign of acupuncture on the right
ankle. Blood, urine, brain, liver and kidney were obtained at the
autopsy.
Materials and Methods
Reagents, chemicals and standards
All reagents were of analytical grade and were stored as indicated
by the supplier. Ethyl acetate, 2-propanol, dichloromethane, metha-
nol, ammonia, hydrochloric acid 37%, sodium chloride, sodium
bicarbonate, sodium carbonate, anhydrous sodium sulfate sodium
hydroxide, O,N-bis(trimethylsilyl)triﬂuoroacetoamide-trimethylclor-
osilane (BSTFA-1% TMCS), pH 6 buffer were purchased from
Sigma-Aldrich (St. Louis, MO, USA); Thymol and sodium sulfate
were obtained from Farmalabor (Canosa di Puglia, Italy).
MethElute Reagent 0.2M in methanol (TMAH) was from Thermo
Scientiﬁc (Waltham, MA, USA). Propofol was purchased from
Archimica S.p.a (Origgio, Italy). Water (18.2MΩ cm−1) was prepared
by a Milli-Q System (Millipore, Darmstadt, Germany); other common
chemicals were of the highest purity commercially available.
Stock solutions of propofol (0.1, 0.25, 0.50, 1, 2, 3, 10, 20, 25,
50, 100 μg/mL) and thymol (IS; 10, 100, 1,000 μg/mL) were pre-
pared in methanol and stored at 4°C.
GC/MS
The analyses were performed on a HP6890 Series II GC system,
with a split-splitless injection system and an MSD HP5973 MS
detector (Agilent Technologies, Santa Clara, CA, USA) operated in
electron ionization (EI) mode (70 eV). The GC was equipped with
a Rxi®-5Sil MS (5% diphenyl/95% dimethyl polysiloxane, 30m ×
0.25mm i.d., ﬁlm thickness 0.25 μm) capillary column (Restek,
Bellefonte, PA, USA).
GC/MS conditions: splitless; solvent delay, 3.5 min; injector tem-
perature, 280°C; interface transfer line, 280°C; ion source, 280°C;
oven temperature program, initial 70°C, 40°C/min up to 110°C,
then 15°C/min up to 300°C (3min). Helium was used as the carrier
gas at a ﬂow rate of 1.2mL/min. The MS detector was operated in
the scan mode, acquiring ions from m/z 50 to 550. The total analy-
sis time was 21min.
GC/MS-TOF
The analyses were performed on a Dani Master GC system, with a
split-splitless injection system and a Dani Master TOF Plus detector
(Dani Instruments, Cologno Monzese, Italy) operated in EI mode
(70 eV). The GC was equipped with a Rxi®-5 ms (Crossbond®, 5%
diphenyl/95% dimethyl polysiloxane, 10m × 0.10mm i.d., ﬁlm
thickness 0.15 μm) capillary column (Restek, Bellefonte, PA, USA).
The GC/MS conditions: split ratio 100:1; injector temperature,
250°C; interface transfer line, 280°C; ion source, 200°C; oven tem-
perature program, initial 70°C, 20°C/min up to 200°C, then 30°C/
min up to 300°C (17 s). Helium was used as the carrier gas at a ﬂow
rate of 0.5mL/min. The MS detector was operated in the scan
mode, acquiring ions from m/z 50 to 550. The total analysis time
was 8min. The selected ions for quantitative analysis were 163 and
178 for propofol and 135 and 150 for the IS.
Sample preparation and extraction procedure
Blood (1mL), urine (1mL) or bile (250 μL) was added with IS
(100 μL, 10 μg/mL), physiological solution (until a volume of 2mL
was reached), 50mg of a mixture of sodium bicarbonate and carbon-
ate (2/1 w/w) and extracted with ethyl acetate (4mL). The mixture
was put on a rotary shaker (20min, 15 rpm) and then centrifuged
(5min, 5,000 rpm). The organic phase was separated, dried with
sodium sulfate and after centrifugation (5min, 5,000 rpm) the super-
natant was withdrawn and the solvent evaporated with a gentle
stream of nitrogen (40°C). The residue was dissolved in ethyl acetate
(100 μL) before the analysis.
Tissue samples were homogenized with a blender or ball mill,
depending on the quantity of material. The deproteinization of the
biological matrix was performed by means of an ultrasonic bath:
100mg of tissue (brain, liver or kidney) previously added with 4mL
of physiological solution, 50mg of a mixture of sodium bicarbonate
and carbonate (2/1 w/w) and 100 μL of IS (10 μg/mL) were soni-
cated for 15min at room temperature. After 5 min centrifugation, a
clear supernatant was separated and extracted with ethyl acetate
(4 mL). The mixture was placed on a rotary shaker (20min, 15 rpm)
and then centrifuged (5 min, 5,000 rpm). The organic phase was sep-
arated, dried with anhydrous sodium sulfate and after centrifugation
(5 min, 5,000 rpm) the supernatant was withdrawn and the solvent
evaporated with a gentle stream of nitrogen (40°C). The residue was
dissolved in ethyl acetate (100 μL) before the analysis.
Hydrolysis of propofol glucuronide and sulfate in urine and bile
samples
The sample of urine (1 mL) or bile (250 μL) was added with
saline solution until a volume of 2mL and 1mL of 6N hydrochloric
acid was added. The mixture was heated at 105°C for 1 h. After
cooling, IS (100 μL, 10 μg/mL) and 50mg of a mixture of sodium
bicarbonate and carbonate (2/1 w/w) were added. Then the mixtures
were extracted as described before.
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Method validation
The validation was carried out using blood as matrix. The results
are summarized in Table I.
The speciﬁcity was assessed on all the matrices considered by
treating control (blank) blood, urine, bile, brain, liver and kidney
samples as described in “Sample preparation and extraction proce-
dure”. The lack of interfering peaks at the same analyte retention
times conferred acceptable selectivity.
The linearity of the response of the GC/MS-TOF analysis was
assessed for propofol by plotting drug/IS peak area ratios versus the
total amount of drug in the standard solutions, with intervals of
25–2,000 ng/mL of analyte (25; 50; 75; 150; 200; 500; 1,250;
1,500; 2,000 ng/mL). The calibration curve (y = 0,0007x – 0,0204)
gave good correlation coefﬁcients (R2 > 0.9925) over the whole
range.
Accuracy was expressed as the per cent recovery (%REC) evalu-
ated by analyzing, in triplicate, two standard propofol solutions
(500–1,250 ng/mL). The averaged results were found to be satisfac-
tory (mean %REC 86.6 at 500 and 111.1 at 1,250 ng/mL).
Two standard solutions (500–1,000 ng/mL) were analyzed ﬁve
times in the same day and over 5 days in order to evaluate the preci-
sion of the method. The intraday and interday %CV were, respectively,
Table I. Validation parameters
Linearity range 25–2,000 ng/mL
Linearity equation y = 0,0007x – 0,0204 (R2 = 0.9925)
LOD 10 ng/mL
LOQ 25 ng/mL
Intraday Precision %CV 7.55% at 500 ng/mL; 8.51% at 1,000 ng/mL
Interday Precision %CV 9.82% at 500 ng/mL; 5.03% at 1,000 ng/mL
Accuracy %REC 86.6 at 500 and 111.1 at 1,250 ng/mL
Table II. Results of STA (n.d. = not determined)
Specimen Case 1 Case 2
Blood Cotinine Cotinine
Caffeine Caffeine
Urine Nicotine Nicotine
Cotinine Caffeine
Caffeine
Bile Nicotine n.d.
Cotinine
Figure 1. Scan analysis of case 1 blood (a). Mass spectrum of propofol-TMS (b).
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7.55 and 9.82% at 500 ng/mL; 8.51 and 5.03% at 1,000 ng/mL. The
obtained data demonstrated adequate reproducibility.
The LOD and LOQ were also evaluated and were found to be
10 and 25 ng/mL evaluated as the concentration of the analyte
which gives a signal to noise ratio of at least 3 and 10, respectively.
Quantitative analyses on urine, bile and tissues were performed
preparing working standard samples (WSS) as follows: 100 μL of
propofol standard solution (10 μg/mL) were placed in vial and the
solvent evaporated. Blank matrices were added and the samples
were treated as described in the Sample preparation paragraph. WSS
were prepared in triplicate.
Results and Discussion
Method development
STA was carried out on the biological samples of the two cases
received. Blood and urine of both cases were evaluated; however
bile was available only in the ﬁrst case. Case 1 did not test positive
for VOC; however, Case 2 had a blood alcohol concentration of
0.2 g/L. Other non-volatile substances identiﬁed in the cases are
reported in Table II. As noted caffeine, cotinine and nicotine were
identiﬁed in both cases and are considered toxicologically irrelevant.
Of interest is the presence of a chromatographic peak whose mass
spectrum correlated to silanized propofol (Figure 1). Based on the
nature of the two cases, the laboratory proceeded with developing
an analytical method for the quantiﬁcation of propofol in biological
ﬂuids and tissues.
Due to the low recoveries obtained with the original SPE method
(21), a liquid–liquid extraction protocol was developed with ethyl
acetate at pH 9 (bicarbonate/carbonate buffer) to optimize the
extraction of propofol in the organic phase. Thymol was chosen as
internal standard. The extracts were silanized using O,N-bis(tri-
methylsilyl)triﬂuoroacetoamide-trimethylclorosilane (BSTFA-1%
TMCS) as in the STA analysis, but due to the low reproducibility of
the results by GC/MS, the determination of propofol after the liq-
uid–liquid extraction protocol without derivatization was carried
out. Unfortunately, two interfering species were detected: capric acid
in blood and nicotine in urine samples (Figure 2).
At this point the chromatographic system was completely chan-
ged, using fast GC/TOF, with narrower and shorter capillary col-
umns. The fast heating and cooling rate of the GC oven and the fast
acquisition rate of the MS detector, allow high sensitivity and reso-
lution and the chromatographic separation results enhanced
although the shortness of the column. In these conditions, the peak
of propofol was completely separated from those of capric acid and
nicotine (Figure 2). The method was validated using blood as matrix
showing suitable selectivity, accuracy, precision, LOD, LOQ and
linearity in the concentration ranges requested for propofol determi-
nation in biological specimen (5, 12–22).
The optimized method was applied for the determination of pro-
pofol in the biological specimens from the two cases. Urine and bile
samples were hydrolyzed because it is known that most of propofol
is conjugated with glucuronic acid (5). A chromatogram obtained
for the analysis of blood of Case 1 is depicted in Figure 3.
Figure 2. Chromatograms of blood of Case 1 in GC/MS (a) and GC/TOF (b) and urine in GC/MS (c) and GC/TOF (d). A = Propofol; B = capric acid; C = nicotine.
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Toxicological considerations
The results obtained analyzing the biological samples from the two
cases are reported in Table III.
The interpretation of the results should be made with particular
caution. It is still widely debated whether propofol can be used to
suicidal overdose. Several coroners believe that it is not possible to
commit suicide with propofol because the maximum voluntarily
injectable quantity of propofol before losing consciousness is not
sufﬁcient to cause death (23). Death could be caused by a continu-
ous intravenous infusion of the drug, with multiple organs failure
mimicking propofol-related infusion syndrome. The two cases show
very different propofol concentrations especially in blood and urine.
In Case 2 propofol levels, found in blood and urine, were below the
therapeutic range and in accordance with the literature (4–8). Death
was probably caused by the respiratory depression caused by propo-
fol, assumed in uncontrolled conditions. The drug was probably
assumed by an intravenous infusion. In fact the subject was a nurse
and he was found in an operating room with a single sign of acu-
puncture in his arm. So suicidal hypothesis is the most likely.
Case 1 was more complicated. The very high concentration of pro-
pofol found in blood seemed incompatible with a single voluntary
injection of propofol (23). In fact propofol causes very rapid loss of
consciousness. Even an intravenous infusion can hardly be responsi-
ble for a so high concentration.
Examining circumstantial data, the presence of several ampoules
of “Propofol Kabi” in the room where the corpse was found, were
evidenced. The corpse presented several signs of acupuncture. The
police found out that the woman lived in the hotel room with her
mother, also a nurse, in poor conditions; they gambled and had
many debts. Probably they decided to both commit suicide, the
mother injected some vials of propofol to the daughter but then
changed her mind and did not kill herself. Death in the ﬁrst case is
then to be ascribed to an homicide rather than a suicide. In conclu-
sion both deaths were related to propofol poisoning, as demon-
strated by the propofol diffusion in the tissues (Table III). In fact to
conﬁrm the poisoning caused by this drug, also the tissues available
from the autopsy were analyzed and the presence of propofol was
conﬁrmed in all the tissues considered.
In Table IV the blood levels of propofol found in propofol
related deaths from the literature (23) are reported. Blood propofol
concentration of Case 2 is in accordance with that reported in
Table IV for suicide cases. The highest blood concentrations of pro-
pofol in Table IV are related to a case of homicide and to a case of
accidental death of a known propofol abuser. The blood propofol
concentration of Case 1 was even higher. In conclusion, taking into
account literature and circumstatial data it is reasonable to conclude
that death in Case 1 is to be ascribed to a homicide.
Conclusions
A liquid–liquid extraction protocol and a GC/MS and a fast GC/
MS-TOF method for the conﬁrmation of propofol in the biological
ﬂuids was optimized and validated. The concentration of propofol
was determined in blood, urine, bile, brain, liver and kidney of two
suspected cases of poisoning caused by propofol. Data emerging
from autopsy ﬁndings, histopathological exams and the concentra-
tions of propofol evidenced by chemical and toxicological analysis,
on the basis of literature data (4–16), allowed us to establish that
both deaths were due to poisoning caused by propofol. In the ﬁrst
case the concentration of propofol in blood resulted to be 8.1 μg/mL
while in the second one it was 1.2 μg/mL. The very different concen-
trations between the two cases were interpreted in two different
ways: in the ﬁrst case two females, mother and daughter, both
nurses, decided to commit suicide with propofol, stolen by the
daughter in the hospital where she worked. The mother injected
propofol in the ankle of the daughter, but then changed her mind
and did not kill herself. In the second case a nurse committed suicide
with an intravenous infusion of propofol.
Table III. Results of the quantitative determination of propofol in
the biological specimens from the two cases
Specimen Case 1 (μg/mL or μg/g) Case 2 (μg/mL or μg/g)
Blood 8.1 1.2
Urine 0.21 0.0073
Hydrolyzed urine 1,276.6 18.3
Bile 3.28
Hydrolyzed bile 105.7
Brain 31.1 4.7
Liver 52.2 49.1
Kidney 2.3
Table IV. Blood levels of propofol in propofol related deaths (23)
Propofol related deaths Blood level of
propofol (μg/mL)
Accidental deaths
26-year-old male ICU nurse, known propofol
abuser
5.3
27-year-old male nurse anesthetist, chronic
propofol abuser
0.026
44-year-old female nurse anesthetist, chronic
propofol abuser
0.039
21-year-old male layperson, propofol abuser 0.071
38-year-old female anesthesiologist, known
propofol abuser
2.4
Suicides
29-year-old female radiologist 0.22
37-year-old male physician 2.5
Homicide
24-year-old female 4.3
Figure 3. Chromatogram for the determination of propofol in blood of Case 1.
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